Ignite Sports Passion! Join VOOPOO Infinity Contest on November 23rd and Win $5,000 Prize!
17.11.2022 02:37:00 EET | Business Wire | Press release
In such a season filled with passion for sports, People all over the world were excited about the movement. VOOPOO, a vape giant brand that insists on being customer-centric and advocates healthy lifestyle and innovation, initiates the official activity named VOOPOO Infinity Go Go Go on its official website to spark vapers spirit of sport.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221116005025/en/
(Photo: Business Wire)
VOOPOO has previously given its flagship product a special look with the launch of the ARGUS Series Limited Edition, ARGUS MT, ARGUS XT, ARGUS GT II, ARGUS POD, and ARGUS PRO. The VOOPOO Infinity Go Go Go campaign, which was launched at the same time, has attracted the attention of many fans and vapers since its launch.
DIY your artwork and support your favorite team, and win a $5,000 Prize!
On November 23rd, VOOPOO will officially hold the second stage of VOOPOO Infinity Go Go Go on its official website.
On the published activity page, we were surprised to find that VOOPOO also hides a huge benefit, namely a grand prize of $5000. According to the official information, we can find that this will be a DIY contest, which may be related to DIY creating their favorite products. Come to the VOOPOO Infinity Go Go Go activity page, look forward to the announcement of relevant information of this activity. Who will win the grand prize of $5,000?
VOOPOO integrates sports passion like “innovation”, “Persistence” and “Fusion” which meets VOOPOO own brand values into this activity, delivering to its users and fans, even the industry the notions that a healthy lifestyle is the basis of one’s development and infinite innovation shifts the future. For more detailed information about contest rules and award settings, please come to the VOOPOO Infinity Go Go Go activity page on November 23rd.
About VOOPOO
VOOPOO was established in 2017 and has rapidly risen through DRAG products, which have been widely acclaimed globally in a short period. As a high-tech enterprise with R&D, design, manufacturing, and branding, VOOPOO has four major product series — ARGUS, DRAG, VINCI, and V. Currently, VOOPOO has a presence in more than 70 countries in North America, Europe, and Asia.
Website: https://www.voopoo.com/
Instagram: https://www.instagram.com/voopootech_official/
Facebook: https://www.facebook.com/voopooglobal
YouTube: https://www.youtube.com/c/VOOPOO
Tiktok: https://www.tiktok.com/@voopoofans
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221116005025/en/
Contact information
Nical Zhang
PR Manager
Nical.zhang@voopootech.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 09:00:00 EET | Press release
Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, the largest radiology practice in the U.S, with more than 4,000 radiologists in its network. Cognita CXR1 applies a proprietary
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 09:00:00 EET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 09:00:00 EET | Press release
For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network operators over the air in just a few seconds, without sending a technician and with minimal disruption to merchants’ activity. For merchants, the experience is seamless: if a network becomes unstable, the payment terminal can automatically reconnect to another available network, often without the merchant even noticing. This deployment represents one of the first large-scale implementations of the SGP.32 eSIM specifi
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 09:00:00 EET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency 1 , and Core EBITDA 2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 08:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom